Prof Heather Payne and Prof Stéphane Oudard discuss the use of apalutamide in the treatment of nmCRPC based on abstracts presented at the virtual ESMO 2020.
Prof Payne gives a description of nmCRPC and the need for a new treatment approach for this type of cancer. She also compared the benefits and drawbacks of a real world study in testing the efficacy of apalutamide to the phase III SPARTAN clinical trial.
Prof Oudard explained the aims of the SPARTAN phase III trial and the rationale behind using time on the treatment as a proxy for time to disease progression. Reasons behind age dependent early discontinuation of the drug, and health related quality of life proceeding this treatment, were also highlighted.
Both the participants discussed the outcomes of the real life named patient program (NPP) study and the SPARTAN phase III trial and the possible impact these results can have on the clinical treatment of non-metastatic castration resistant prostate cancer (nmCRPC).
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).